Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-05-05
1996-05-21
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514811, A61K 3155
Patent
active
055190170
ABSTRACT:
Galanthamine and the pharmaceutically suitable acid addition salts thereof can be used for the treatment of alcoholism; these compounds are released from adequate pharmaceutic formulations which are administered, e.g., orally, transdermally, or otherwise parenterally, in a continuous and controlled manner.
REFERENCES:
patent: 4663318 (1987-05-01), Davis
patent: 4761429 (1988-08-01), Blum et al.
patent: 4777173 (1988-10-01), Shrotryia et al.
patent: 4954504 (1990-09-01), Chen et al.
patent: 5152994 (1992-10-01), Lotsof
Bickel, U., Thomsen, T., Weber, W., Fischer, J. P., Bachus, R., Nitz, M., Kewitz, H.: "Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition." Clin. Pharmacol. Ther., 50: 420-28 (1991).
Cozanitis, D. A., Toivakka, E.: "Treatment of respiratory depression with the anticholinesterase drug galanthamine hydrobromide." Aneasthesia, 29: 581-84 (1974).
Cozanitis, D. A.: "Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of Scopolamine (Hyoscine)." Anaesthesist, 26: 649-50 (1977).
Cozanitis, D. A., van de Pol, F., van Wezel, H., Crul, J. F.: "Antagonistic activity of galanthamine on constant infusion of pancuronium in rats." Experientia, 37: 1326-27 (1981).
Cozanitis, D. A., Friedmann, T., Furst, S.: "Study of the analgesic effects of Galanthamine, a Cholinesterase Inhibitor." Archives Intern. de Pharmacodynamie et de Therapie, 266: 229-38 (1983).
Foitzik, H., Lawin, P.: "Klinische Erfahrungen mit Galanthamin (Nivalin) als Antidot von Pancuronium." Z. prakt. Anasth., 7: 203-7 (1972).
Gopel, W., Bertram, W.: "Erfahrungen mit Nivalin in der neurologischen Therapie." Psychiat. Neurol. med. Psychol., 23: 712-18 (1971).
Mayrhofer, O.: "Erfahrungen mit Galanthamin (Nivalin als Antagonist der Relaxantien vom Curaretyp." Bull. schweiz. Akad. med. Wiss., 23: 48-52 (1967).
Mihailova, D., Yamboliev, I., Zhivkova, Z., Tencheva, J., Jovovich, V.: "Pharmacokinetics of Galanthamine Hydrobromide after single subcutaneous and oral dosage in humans." Pharmacology, 39: 50-58 (1989).
Naranjo, C. A., Sellers, E. M. (Ed.): "Drug treatments for alcoholism: The need for innovation." in: Research Advances in New Psychoparm. Treatments for Alcoholism, 1-9 Elsevier Science Publishers B.V. (1985).
Paskov, D. S.: "Galanthamine." in: New Neuromuscular Blocking Agents, 31:653-72 Springer-Verlag Berlin, Heidelberg, New York, Tokyo (Ed.) (1986).
Snorrason, E., Stefansson, J. G.: "Galanthamine hydrobromide in mania." Lancet, 337: 557 (1991).
Stojek, A., Napierala, K.: "Physostigmine in eyedrops decreases craving for alcohol in early with withdrawal treated with carbamazepine." Materia Medica Polona, 4: 249-54 (1986).
Tanahashi, T., Poulev, a., Zenk, M. H.: "Radioimmunoassay for the quantitative determination of Galanthamine." Planta Medica, 56: 77-81 (1990).
Tencheva, J., Yamboliev, I., Zhivkova, Z.: "Reversed-phase liquid chromatography for the determination of galanthamine and its metabolites in human plasma and urine." Journal of Chromatography, 421: 396-400 (1987).
Thomsen, T., Bickel, U., Fischer, J. P., Kewitz, H.: "Stereoselectivity of cholinesterase inhibition by galanthamine and Eur. J. Clin. Pharmacol. and tolerance in humans" 39: 603-5 (1990).
Thomsen, T., Zendeh, B., Fischer, J. P., Kewitz, H.: "In vitro effects of various cholinesterase inhibitors on acetyl-- and butyrylchloinesterase of healthy volunteers." Biochemical Pharmacology, 41: 139-41 (1991).
Thomsen, T., Kaden, B. Fischer, J. P., Bickel, U., Barz, H., Gusztony, G., Cervos-Navarro, J. Kewitz, H.: "Inhibition of Acetylcholinesterase activity in human brain tissue and erythrocytes by Galanthamine, Physostigmine and Tacrine." Eur. J. Clin. Chem. Clin. Biochem., 29: 487-92 (1991).
Thomsen, T., Kewitz, H.: "Selective inhibition of human acetylcholinsterase by Galanthamine in vitro and in vivo." Life Sciences, 46: 1553-58 (1990).
Vlahov, R., Krikorian, D., Spassov, G., Chinova, M., Vlahov, I., Parushev, S., Snatzke, G., Ernst, L., Kieslich, K., Abraham, W.-R., Sheldrick, W. S.: "Synthesis of Galanthamine and related alkaloids-New approaches." Tetrahedron, 45: 3329-45 (1989).
J. Ruprecht et al: "The involvement of the central cholinergic and endorphinergic systems in the nitrous oxide withdrawal syndrome in mice." Anesthesiology, V. 58, No. 6, 1983, pp. 524-526.
Haboubi, N. A. et al, Ann. Clin. Biochem. 23(4): 458-62, 1986.
Hsu, L. L. et al., Alcohol Clin Exp Res 7(3); 249-55, 1983.
Stojek, A. et al., BR J Addict 82(8): 927-30; 1907.
Daunderer, M., Fortschr Med 101 (17); 778-80, 1983.
Power, J. S. et al.; J. Clin. Pharmacol. 21(1); 57-60, 1981.
Riley, E. P. et al., Alcohol Clin Exp Res 10(1); 50-53, 1986.
Rupreht, J. et al., Anesthesiology, 58(6), pp. 524-526, 1983.
Goodman Gilman et al., The Pharmacological Basis of Therapeutics (6th Ed.) Macmillan Publ. Co., N.Y., 1980, pp. 552-553.
Cintins Marianne M.
Hefa-Frenon Arzneimittel GmbH & Co. KG
LTS Lohmann Therapie-Systeme GmbH & Co. KG
Moezie M.
LandOfFree
Pharmaceutic formulation for the treatment of alcoholism does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutic formulation for the treatment of alcoholism, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutic formulation for the treatment of alcoholism will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2038165